These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 21640482)

  • 1. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
    Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study.
    Dorin RP; Daneshmand S; Eisenberg MS; Chandrasoma S; Cai J; Miranda G; Nichols PW; Skinner DG; Skinner EC
    Eur Urol; 2011 Nov; 60(5):946-52. PubMed ID: 21802833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.
    May M; Herrmann E; Bolenz C; Tiemann A; Brookman-May S; Fritsche HM; Burger M; Buchner A; Gratzke C; Wülfing C; Trojan L; Ellinger J; Tilki D; Gilfrich C; Höfner T; Roigas J; Zacharias M; Gunia S; Wieland WF; Hohenfellner M; Michel MS; Haferkamp A; Müller SC; Stief CG; Bastian PJ
    Eur Urol; 2011 May; 59(5):712-8. PubMed ID: 21296488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response.
    Seiler R; Thalmann GN; Rotzer D; Perren A; Fleischmann A
    Mod Pathol; 2014 Jan; 27(1):87-95. PubMed ID: 23887292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
    Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
    J Urol; 2001 Jul; 166(1):19-23. PubMed ID: 11435814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
    Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ
    Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
    Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
    Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
    Wright JL; Lin DW; Porter MP
    Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer.
    Seiler R; von Gunten M; Thalmann GN; Fleischmann A
    Histopathology; 2011 Mar; 58(4):571-8. PubMed ID: 21401697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
    Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
    Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients.
    Seiler R; von Gunten M; Thalmann GN; Fleischmann A
    Hum Pathol; 2012 Feb; 43(2):269-75. PubMed ID: 21835428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.